bioAffinity Technologies, Inc. — Form 8-K
Filed August 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
bioAffinity Technologies implemented a 1-for-15 reverse stock split effective August 24, 2026, reducing outstanding shares from approximately 8.88M to 592,373 shares. The split was stockholder-approved on April 30, 2026, and is intended to restore Nasdaq minimum bid price compliance. Fractional shares are paid out in cash at the 10-day average closing price preceding the effective date.
Why this rating
Reverse split is structural remedy for Nasdaq compliance, not fundamental business change. Neutral to slightly negative—no revenue or product impact, but signals prior stock weakness and carries execution/liquidity risk.
See more from August 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.